Small molecule modulation of microbiota: a systems pharmacology perspective

Area of Science:

• Microbiome research
• Pharmacology
• Systems biology

Background:

• Microbes are linked to human diseases and drug effectiveness.
• Current microbiome drug discovery uses a limited "one-drug-one-target" approach.
• A systematic pharmacology strategy offers a promising alternative.

Purpose of the Study:

• To develop a systematic approach for microbiome-targeted drug discovery.
• To identify potential drug targets within microbial communities.
• To explore novel therapeutic strategies for microbiome-associated diseases.

Main Methods:

• Constructed a disease-centric signed microbe-microbe interaction network.
• Developed a Signed Random Walk with Restart algorithm for predicting microbe effects.
• Analyzed the druggability and evolutionary space of microbial proteins.

Main Results:

• Identified that 8-10% of microbial proteins are targetable by existing drugs.
• Found 25% of microbial proteins have human homologs.
• Demonstrated that diabetes drugs could serve as lead compounds for microbiota therapeutics.
• Highlighted periplasmic and outer membrane proteins as specific targets in pathogenic microbes.

Conclusions:

• Systematic polypharmacology of the microbiome network opens new avenues for drug discovery.
• Applying systematic methods to polypharmacological investigations can lead to novel therapies.
• This approach promises to advance the development of microbiome-targeted therapeutics.